Newsroom
Strive to Deliver Breakthroughs
CAMBRIDGE, Mass., February 14, 2023 Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Onc...
View moreHBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform HBM1022 presented cynomolgus ...
View moreCambridge, MA, January 26, 2023 HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142...
View moreHBM1007 is a fully-human monoclonal antibody targeting CD73 HBM1007 is generated from Harbour Mice® H2L2 platform With unique epitopes to...
View moreHBM1020 is the globally first-in-class fully human monoclonal antibody targeting B7H7. HBM1020 is also the globally first-ever monoclonal antibody targeti...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN— December 8, 2022 Harbour BioMed (the “Company”, HKEX: 02142), today announced the pro...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN— Nov 25, 2022 Harbour BioMed (the “Company”, HKEX: 02142), today announced that ...
View moreCAMBRIDGE, MA— November 21, 2022 Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2022 Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned sub...
View more